On September 2, 2025, Ionis Pharmaceuticals announced positive results from Phase 3 studies of olezarsen, showing a placebo-adjusted reduction in fasting triglycerides of up to 72% and an 85% reduction in acute pancreatitis events. This significant outcome indicates the drug's strong efficacy in treating severe hypertriglyceridemia.